Key result
Cisplatin chemotherapy is linked to reversible profound bradycardia with heart rates dropping below ~45 bpm.
Why the study?
Cisplatin is considered safe regarding cardiotoxicity, but cases of bradycardia during cisplatin therapy have been reported and need further characterization.
Case Report (n=2)
No
Cisplatin is a platinum-containing drug that inhibits DNA synthesis by inhibiting cross-linking, denaturing DNA strands. It is used in combination with other chemotherapeutic agents to treat several types of cancers. Numerous adverse effects have been reported with this compound. However, it is considered a safe medication in terms of cardiotoxicity. In this report, we discuss the case of two patients who experienced bradycardia while receiving cisplatin as part of combination therapy. A workup was undertaken to rule out other possible causes of bradycardia, and the diagnosis of cisplatin-induced bradycardia was made.
No takes yet. Share an insight, caveat, or question.
Naeem et al. (2021) conducted a case report in Malignancy (Testicular germ cell tumor and T cell-rich B-cell lymphoma) (n=2). Cisplatin was evaluated. Cisplatin administration induced profound, reversible bradycardia with heart rates dropping to 43 and 46 beats per minute in two young male patients undergoing combination chemotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: